Vol. 21 No. 1 (2017)
ENDOVASCULAR SURGERY: SPECIAL TOPIC

Percutaneous coronary intervention with ABSORB biodegradable vascular scaffold in patients with left anterior descending artery disease

PDF (Русский)
  • K. Vakkosov,
  • A. Shilov,
  • R. Tarasov,
  • V. Ganjukov,
  • O. Barbarash
K. Vakkosov
Research Institute for Complex Issues of Cardiovascular Diseases, 650002 Kemerovo, Russian Federation
Bio
A. Shilov
Research Institute for Complex Issues of Cardiovascular Diseases, 650002 Kemerovo, Russian Federation
R. Tarasov
Research Institute for Complex Issues of Cardiovascular Diseases, 650002 Kemerovo, Russian Federation
V. Ganjukov
Research Institute for Complex Issues of Cardiovascular Diseases, 650002 Kemerovo, Russian Federation
O. Barbarash
Research Institute for Complex Issues of Cardiovascular Diseases, 650002 Kemerovo, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2017-1-56-61

Published 2017-04-25

Keywords

  • coronary artery disease,
  • percutaneous coronary intervention,
  • biodegradable vascular scaffold Absorb

How to Cite

Vakkosov, K., Shilov, A., Tarasov, R., Ganjukov, V., & Barbarash, O. (2017). Percutaneous coronary intervention with ABSORB biodegradable vascular scaffold in patients with left anterior descending artery disease. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 21(1), 56–61. https://doi.org/10.21688/1681-3472-2017-1-56-61

Copyright (c) 2017 Vakkosov K.M., Shilov A.A., Tarasov R.S., Ganjukov V.I., Barbarash O.L.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Aim. The article evaluates 30-day results of percutaneous coronary intervention (PCI) with ABSORB biodegradable vascular scaffold (BVS) implanted in the case of stenosis of the left anterior descending (LAD) coronary artery in patients with stable angina.
Methods. 64 patients with significant (≥ 70%) LAD disease were included in the study. At 30 days, scaffold thrombosis and major adverse cardiovascular events (all-cause mortality, myocardial infarction, stroke, target vessel revascularization) were evaluated. The indicator of successful percutaneous coronary intervention (residual stenosis ≤20% in the presence of counterpulsation corresponding to TIMI 3rd Grade and in the absence of significant in-patient clinical complications) and successful intervention assessed by clinical criteria (successful percutaneous coronary intervention alongside with a decrease in objective and subjective symptoms of myocardial ischemia, or their complete disappearance) were also analyzed.
Results. Mean age of patients was 61.6±8.5 years, with males accounting for 64%; 33% had earlier MI, 14% – diabetes mellitus. Mean left ventricular ejection fraction was 61.3±6.8%. Left anterior descending artery disease was presented in 89% of patients with SYNTAX Score 6.6±2.2. Mean number of implanted stents was 1.2±0.4, with mean length of the stented segment equal to18.7±1.8 mm and mean diameter 3.2±0.3 mm. At 30-day follow-up, the success of intervention assessed by clinical criteria amounted to 96.9% (n=62); that of myocardial infarction 3.1% (n=2); stent thrombosis 1.56% (n=1); repeated revascularization 1.56% (n=1); major adverse cardiovascular events (MACE) 3.1%.
Conclusion. The implantation of everolimus-eluting BVS for LAD stenosis demonstrates satisfactory results at 30-day follow-up.

Received 16 January 2017. Accepted 21 March 2017.

Financing: The study did not have sponsorship.

Conflict of interest: The authors declare no conflict of interest.

PDF (Русский)

References

  1. Serruys P., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emanuelsson H., Marco J., Legrand V., Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489-95. https://doi.org/10.1056/NEJM199408253310801
  2. Garg S., Serruys P. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56(10 Suppl):S43-78. https://doi.org/10.1016/j.jacc.2010.06.008
  3. Räber L., Wohlwend L., Wigger M., Togni M., Wandel S., Wenaweser P., Cook S., Moschovitis A., Vogel R., Kalesan B., Seiler C., Eberli F., Lüscher T., Meier B., Jüni P., Windecker S. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation. 2011;123(24):2819-28. https://doi.org/10.1161/CIRCULATIONAHA.110.004762
  4. Kereiakes D., Yeh R., Massaro J., Driscoll-Shempp P., Cutlip D., Steg P., Gershlick A., Darius H., Meredith I., Ormiston J., Tanguay J., Windecker S., Garratt K., Kandzari D., Lee D., Simon D., Iancu A., Trebacz J., Mauri L.; DAPT Study Investigators. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC Cardiovasc Interv. 2015;8(12):1552-62. https://doi.org/10.1016/j.jcin.2015.05.026
  5. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M., Schömig A., Pfisterer M., Stone G., Leon M., de Lezo J., Goy J., Park S., Sabaté M., Suttorp M., Kelbaek H., Spaulding C., Menichelli M., Vermeersch P., Dirksen M., Cervinka P., Petronio A., Nordmann A., Diem P., Meier B., Zwahlen M., Reichenbach S., Trelle S., Windecker S., Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-48. https://doi.org/10.1016/S0140-6736(07)61444-5
  6. Bangalore S., Kumar S., Fusaro M., Amoroso N., Attubato M., Feit F., Bhatt D., Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873-91. https://doi.org/10.1161/CIRCULATIONAHA.112.097014
  7. Ormiston J., Serruys P., Regar E., Dudek D., Thuesen L., Webster M., Onuma Y., Garcia-Garcia H., Mreevy R., Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet. 2008;371(9616):899-907. https://doi.org/10.1016/S0140-6736(08)60415-8
  8. Ellis S., Kereiakes D., Metzger D., Caputo R., Rizik D., Teirstein P., Litt M., Kini A., Kabour A., Marx S., Popma J., McGreevy R., Zhang Z., Simonton C., Stone G.; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):1905-15. https://doi.org/10.1056/NEJMoa1509038
  9. Capodanno D., Joner M., Zimarino M. What about the risk of thrombosis with bioresorbable scaffolds? EuroIntervention. 2015;11 Suppl V:V181-4. https://doi.org/10.4244/EIJV11SVA43
  10. Lipinski M., Escarcega R., Baker N., Benn H., Gaglia M. Jr, Torquson R., Waksman R. Scaffold thrombosis after percutaneous coronary intervention with Absorb Bioresorbable Vascular Scaffold: A systematic review and meta-analysis. JACC Cardiovasc Interv. 2016;9(1):12-24. https://doi.org/10.1016/j.jcin.2015.09.024
  11. Planer D., Smits P., Kereiakes D., Kedhi E., Fahy M., Xu K., Serruys P., Stone G. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes pooled results from the SPIRIT (a clinical evaluation of the XIENCE V everolimus eluting coronary stent system) and COMPARE (a trial of everolimus-eluting stents and paclitaxel-eluting stents for coronary revascularization in daily practice) trials. JACC Cardiovasc Interv. 2011;4(10):1104-15. https://doi.org/10.1016/j.jcin.2011.06.018
  12. Machado C., Raposo L., Dores H., Leal S., Campante Teles R., de Araújo Gonçalves P., Mesquita Gabriel H., Almeida M., Mendes M. Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease. Coron Artery Dis. 2014;25(3):208-14. https://doi.org/10.1097/MCA.0000000000000078
  13. Grundeken M., Wykrzykowska J., Ishibashi Y., Garg S., de Vries T., Garcia-Garcia H., Onuma Y., de Winter R., Buszman P., Linke A., Ischinger T., Klauss V., Eberli F., Corti R., Wijns W., Morice M., di Mario C., Meier B., Jüni P.,. Yazdani A., Copt S., Windecker S., Serruys P. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-Year follow-up of the LEADERS all-comers randomized trial. Catheter Cardiovasc Interv. 2016;87(7):E248-60. https://doi.org/10.1002/ccd.26344
  14. Tamburino C., Latib A., van Geuns R., Sabate M., Mehilli J., Gori T., Achenbach S., Alvarez M., Nef H., Lesiak M., Di Mario C., Colombo A., Naber C., Caramanno G., Capranzano P., Brugaletta S., Geraci S., Araszkiewicz A., Mattesini A., Pyxaras S., Rzeszutko L., Depukat R., Diletti R., Boone E., Capodanno D., Dudek D. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015;11:45-52. https://doi.org/10.4244/EIJY15M01_05
  15. Mattesini A., Secco G., Dall’Ara G., Ghione M., Rama-Merchan J., Lupi A., Viceconte N., Lindsay A., De Silva R., Foin N., Naganuma T., Valente S., Colombo A., Di Mario C. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv. 2014;7:741-50. https://doi.org/10.1016/j.jcin.2014.01.165